At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,733 enrolled
Drug / intervention
Tafamidisdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
In Brief
A Phase 3 clinical trial evaluating Tafamidis for Transthyretin (TTR) Amyloid Cardiomyopathy. Completed, enrolled 1,733 participants across 80 sites in 17 countries.
Detailed Summary
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hong Kong, Italy, Japan, Netherlands, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJun 2016
Primary CompletionOct 2023
Study CompletionNov 2023
TodayJul 2026
First PostedJun 6, 2016
Enrollment StartJun 13, 2016
Primary CompletionOct 26, 2023
Study CompletionNov 2, 2023
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 10.1 years ago
Interventions
Tafamidisdrug
Soft gel capsules administered once a day for 60 months